ASCO Annual Meeting
Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Presented by, Douglas R. Adkins, M.D., Professor of Medicine, Washington University School of Medicine, St. Louis, and a principal investigator participating in the CUE-101 clinical trial
ASCO Annual Meeting
Poster Presentation: A phase 1 dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in HLA-A*0201- positive patients with WT1-positive recurrent/metastatic cancers
SITC Annual Meeting
Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
SITC Annual Meeting
Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
ASCO Annual Meeting
Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
SITC Annual Meeting
Poster Presentation: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
SITC Annual Meeting
Poster Presentation: A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
SITC Annual Meeting
Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies
American Society of Clinical Oncology (ASCO)
Poster Presentation: A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Frontiers in Cancer Immunotherapy Conference 2022 NYAS
Poster Presentation: CUE-102 Selectively Activates and Expands WT1-Specific T Cells for the Treatment of Patients with WT1+ Malignancies
BPS Annual Meeting
Poster Presentation: Integration of IL-2 signaling at the immunological synapse
SITC Annual Meeting
Poster Presentation: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
SITC Annual Meeting
Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies
T-Cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice
The Journal of Clinical Investigation; October 21, 2021 DOI: 10.1172/JCI141051
Peptide‑HLA‑based immunotherapeutics platforms for direct modulation of antigen‑specific T cells
Nature Portfolio, Scientific Reports; September 28, 2021 DOI: 10.1038/s41598-021-98716-z
FOCIS Annual Meeting
Video: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction of CD4+ FOXP3+ regulatory T cells
Frontiers in Cancer Immunotherapy Conference
Poster Presentation: Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: Targeting Tumor Heterogeneity and Tumor Escape Mechanisms
ASIT Summit
Presentation: Directly Targeting Autoantigen-Specific T cells with Immuno-STATs
In vivo detection of antigen-specific CD8+ T cells by immuno-positron emission tomography
Nature Methods 2020; September 14, 2020 DOI: 10.1038/s41592-020-0934-5
PEGS Boston
Video Poster Presentation: Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity
Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex
PLOS One 2020; June 4, 2020 DOI: 10.1371/Journal PONE.0233578
CUE-101, a Novel HPV16 E7 pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
Clinical Cancer Research 2020; January 21, 2020 DOI: 10.1158/1078-0432.CCR-19-3354
SITC Annual Meeting
Poster Presentation: CUE-101, a Novel HPV16 E7:pMHC:IL-2:Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
Keystone Symposia
Poster Presentation: CUE-101, a novel Fc fusion protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies
SITC 2022
November, 2022
Dr. Christine Chung presents new clinical data on CUE-101.
Many thanks to Dr. Chung, the Moffitt Cancer Center and their Marketing Team
Watch Now »
Cell & Gene
March, 2022
Restoration of Immune Balance
Listen Now »
Empowered Patient Podcasts
March 3, 2020
December 4, 2019